Boston Scientific has just announced plans to launch new fractional flow reserve and atherectomy guidewires in 2015 in collaboration with Japanese medical component specialist Asahi Intecc.
Columbia University scientists showed that it is possible to control the size of the blood-brain barrier opening by varying the pressure of an ultrasound beam, a discovery that could herald major breakthroughs in the treatment of neurological diseases.
Back in January, the prestigious Sanford-Burnham Medical Research Institute amended its ethos, promising to more closely marry its work to therapeutic development and become a partner of choice for drugmakers. Now, the 38-year-old organization has chosen the leader to get it there, convincing GlaxoSmithKline's Perry Nisen to take the reins as its new CEO.
Aspergillus is a mold that infects the respiratory system and can lead to serious illness or death in patients with weakened immune systems. Researchers believe they've found the ideal combination of tests for early, effective diagnosis.
Abbott Laboratories and the United States Department of Defense are collaborating to develop a test that can be used to assess potential concussions quickly in the field. Abbott's handheld diagnostic i-Stat System is already in use by the military; the test will be developed for use on it.
What's that about Bart Becht's shadow? Don't ask Reckitt Benckiser CEO Rakesh Kapoor. He's not living in it.
Maryland CRO ABL has signed a deal with Expression Therapeutics to to handle cell line development studies and help the biotech produce a treatment for hemophilia A.
Patients implanted with heart rhythm devices that automatically send information about cardiac abnormalities to a telemonitoring center showed improved outcomes in heart failures and fewer deaths than those without the remote monitoring leads, according to a new study.
Teva Pharmaceutical is rolling its troubled CNS drug laquinimod into a mid-stage study in Huntington's disease, looking to expand the potential of a treatment marked by clinical and regulatory setbacks.
Dutch drug developer ProQR Therapeutics is swinging for a $75 million Wall Street debut to fund its work on a treatment for cystic fibrosis, looking to compete with market leader Vertex Pharmaceuticals.